The power of monoclonal antibodies as agents of discovery: CD40 revealed as a B lymphocyte costimulator

Journal of Immunology

Volumn 188, Issue 9, 2012, Pages 4127-4129

  Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD20 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G28 5; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; HUMAN; HYBRIDOMA CELL CULTURE; LYMPHOCYTE PROLIFERATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; CELL CYCLE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION;

EID: 84860324657     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200775     Document Type: Article

References (45)

1. Köhler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
2. Clark, E. A., and J. A. Ledbetter. 1986. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA 83: 4494-4498. (Pubitemid 16057075)
3. Clark, E. A., G. Shu, and J. A. Ledbetter. 1985. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770. (Pubitemid 15085258)
4. Bishop, G. A. 2009. The many faces of CD40: multiple roles in normal immunity and disease. Semin. Immunol. 21: 255-256.
5. Paulie, S., B. Ehlin-Henriksson, H. Mellstedt, H. Koho, H. Ben-Aissa, and P. Perlmann. 1985. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother. 20: 23-28. (Pubitemid 15238919)
6. Stamenkovic, I., E. A. Clark, and B. Seed. 1989. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 8: 1403-1410. (Pubitemid 19274364)
7. Bishop, G. A., and B. S. Hostager. 2003. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 14: 297-309. (Pubitemid 36693149)
8. Spriggs, M. K., R. J. Armitage, L. Strockbine, K. N. Clifford, B. M. Macduff, T. A. Sato, C. R. Maliszewski, and W. C. Fanslow. 1992. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J. Exp. Med. 176: 1543-1550.
9. Wheeler, K., J. D. Pound, J. Gordon, and R. Jefferis. 1993. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur. J. Immunol. 23: 1165-1168. (Pubitemid 23120182)
10. Defrance, T., B. Vanbervliet, F. Briere, I. Durand, F. Rousset, and J. Banchereau. 1992. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 175: 671-682.
11. Banchereau, J., P. de Paoli, A. Vallé, E. Garcia, and F. Rousset. 1991. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251: 70-72. (Pubitemid 21916853)
12. Armitage, R. J., B. M. Macduff, M. K. Spriggs, and W. C. Fanslow. 1993. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J. Immunol. 150: 3671-3680. (Pubitemid 23129748)
13. Bishop, G. A., W. D. Warren, and M. T. Berton. 1995. Signaling via major histocompatibility class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur. J. Immunol. 25: 1230-1238.
14. Vanden Bush, T. J., and G. A. Bishop. 2008. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur. J. Immunol. 38: 400-409.
15. Broomfield, S. A., R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. S. Robinson, and A. J. Currie. 2009. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182: 5217-5224.
16. Rieger, R., and T. J. Kipps. 2003. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 63: 4128-4135. (Pubitemid 36917937)
17. Kaku, H., and T. L. Rothstein. 2009. Fas apoptosis inhibitory molecule enhances CD40 signaling in B cells and augments the plasma cell compartment. J. Immunol. 183: 1667-1674.
18. Thomas, M., M. Calamito, B. Srivastava, I. Maillard, W. S. Pear, and D. Allman. 2007. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood 109: 3342-3350. (Pubitemid 46572522)
19. Holder, M. J., H. Wang, A. E. Milner, M. Casamayor, R. Armitage, M. K. Spriggs, W. C. Fanslow, I. C. M. MacLennan, C. D. Gregory, J. Gordon, et al. 1993. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur. J. Immunol. 23: 2368-2371. (Pubitemid 23265908)
20. Illera, V. A., C. E. Perandones, L. L. Stunz, D. A. Mower, Jr., and R. F. Ashman. 1993. Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. J. Immunol. 151: 2965-2973. (Pubitemid 23282609)
21. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, S. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-564.
22. Shapira, S. K., D. Vercelli, H. H. Jabara, S. M. Fu, and R. S. Geha. 1992. Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J. Exp. Med. 175: 289-292.
23. Choi, M. S. K., R. D. Brines, M. J. Holman, and G. G. B. Klaus. 1994. Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1: 179-187.
24. Mo, C., B. Vire, and A. Wiestner. 2010. Rituximab: therapeutic benefit! Vitamin R? Semin. Hematol. 47: 105-106.
25. Léveillé, C., R. AL-Daccak, and W. Mourad. 1999. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur. J. Immunol. 29: 65-74. (Pubitemid 29043523)
26. Anolik, J., R. J. Looney, A. Bottaro, I. Sanz, and F. Young. 2003. Down-regulation of CD20 on B cells upon CD40 activation. Eur. J. Immunol. 33: 2398-2409. (Pubitemid 37138972)
27. Jak, M., G. G. van Bochove, E. A. Reits, W. W. Kallemeijn, J. M. Tromp, P. Umana, C. Klein, R. A. van Lier, M. H. J. van Oers, and E. Eldering. 2011. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood 118: 5178-5188.
28. Benoit, N. E., and W. F. Wade. 1996. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface Ig. Immunopharmacology 35: 129-139. (Pubitemid 26387597)
29. Smiers, F. J., M. van Paassen, K. Hählen, B. Löwenberg, and I. P. Touw. 1996. CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia. Br. J. Haematol. 93: 125-130. (Pubitemid 26130721)
30. Loskog, A. S. I., and A. G. Eliopoulos. 2009. The Janus faces of CD40 in cancer. Semin. Immunol. 21: 301-307.
31. Larson, A. W., and T. W. LeBien. 1994. Cross-linking CD40 on human B cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus. J. Immunol. 153: 584-594. (Pubitemid 24206287)
32. Peters, A. L., L. L. Stunz, and G. A. Bishop. 2009. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 21: 293-300.
33. Engel, D., T. Seijkens, M. Poggi, M. Sanati, L. Thevissen, L. Beckers, E. Wijnands, D. Lievens, and E. Lutgens. 2009. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin. Immunol. 21: 308-312.
34. Law, C.-L., and I. S. Grewal. 2009. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. In Therapeutic Targets of the TNF Superfamily. Grewal, I. S., ed. Landes Bioscience, Austin, TX, p. 8-36.
35. Armitage, R. J., W. C. Fanslow, L. Strockbine, T. A. Sato, K. N. Clifford, B. M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, et al. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357: 80-82.
36. Hollenbaugh, D., L. S. Grosmaire, C. D. Kullas, N. J. Chalupny, S. Braesch-Andersen, R. J. Noelle, I. Stamenkovic, J. A. Ledbetter, and A. Aruffo. 1992. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 11: 4313-4321.
37. Lane, P., A. Traunecker, S. Hubele, S. Inui, A. Lanzavecchia, and D. Gray. 1992. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur. J. Immunol. 22: 2573-2578.
38. DiSanto, J. P., J. Y. Bonnefoy, J. F. Gauchat, A. Fischer, and G. de Saint Basile. 1993. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361: 541-543. (Pubitemid 23055616)
39. Fuleihan, R., N. Ramesh, R. Loh, H. Jabara, R. S. Rosen, T. Chatila, S. M. Fu, I. Stamenkovic, and R. S. Geha. 1993. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc. Natl. Acad. Sci. USA 90: 2170-2173. (Pubitemid 23078587)
40. Korthäuer, U., D. Graf, H. W. Mages, F. Brière, M. Padayachee, S. Malcolm, A. G. Ugazio, L. D. Notarangelo, R. J. Levinsky, and R. A. Kroczek. 1993. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361: 539-541. (Pubitemid 23055615)
41. Puck, J. M. 1994. Molecular and genetic basis of X-linked immunodeficiency disorders. J. Clin. Immunol. 14: 81-89. (Pubitemid 24108794)
42. Castigli, E., F. W. Alt, L. Davidson, A. Bottaro, E. Mizoguchi, A. K. Bhan, and R. S. Geha. 1994. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc. Natl. Acad. Sci. USA 91: 12135-12139. (Pubitemid 24368619)
43. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1: 167-178.
44. Xu, J., T. M. Foy, J. D. Laman, E. A. Elliott, J. J. Dunn, T. J. Waldschmidt, J. Elsemore, R. J. Noelle, and R. A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity 1: 423-431.
45. Grewal, I. S., J. Xu, and R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378: 617-620.